Results for "Hims & Hers"

Law firms have announced securities class action lawsuits against York Space Systems, Innventure, and Hims & Hers Health, urging investors to review potential claims amid alleged stock price declines.

The chief executive of telehealth company Hims & Hers publicly challenged the Federal Trade Commission, arguing that regulators lack a fundamental understanding of the firm's operations and compliance framework.

Analysis suggests Hims & Hers Health could capitalize on the expanding GLP-1 weight-loss medication market through direct-to-consumer sales and telehealth integration.

Scott+Scott Attorneys at Law LLP has issued an investor alert, announcing an investigation into Hims & Hers Health, Inc.'s directors and officers for potential breach of fiduciary duties.

The CEO of Hims & Hers stated that companies with their own large datasets can achieve significant cost savings, up to 80%, by utilizing open-weight AI models.

Hims & Hers (HIMS) has raised its guidance, prompting questions about whether its growth can be sustained following a margin reset related to GLP-1 treatments.

Hims & Hers stock is trimming its earlier losses after the company released its latest quarterly financial results, indicating a market reaction to the performance report.

Several stocks, including Riot Platforms, Hims & Hers Health, and Intel, are experiencing significant movements in premarket trading.

An analysis questions whether the recent sharp decline in Hims & Hers Health stock presents a potential buying opportunity for investors.

Shares of Hims & Hers fell after reports emerged regarding a potential lawsuit from the Federal Trade Commission (FTC).

Shares of Hims & Hers declined following a decision by FDA advisors regarding the company's first peptide product.

Shares of Hims & Hers (HIMS) surged by 12.5% as the company benefits from growing momentum in the obesity treatment market.

Shares of Hims & Hers increased following an insider purchase of over $1 million in the company's stock.

Despite Hims & Hers reporting an earnings miss last week, an analysis suggests there is a positive aspect or "silver lining" to the financial results.

Hims & Hers stock experienced a decline after the company announced a proposed $300 million convertible debt offering.

Hims & Hers is making significant investments in GLP-1 drugs, but investors are expressing a desire for the company to deliver profits in the short term.

Despite missing its first-quarter earnings estimates, Hims & Hers is reportedly gaining bullish views from analysts.

JPMorgan has reduced its price target for Hims & Hers, citing a shift in the GLP-1 market that is reshaping the company's growth trajectory. This adjustment reflects changing market dynamics impacting the healthcare sector.

Hims & Hers shares experienced a significant plunge in premarket trading after the company reported a first-quarter loss and revenue figures that fell short of analyst estimates, impacted by its pivot to branded GLP-1s.

Several companies including Hims & Hers, Gitlab, Cleanspark, and Webtoon Entertainment saw significant stock movements in after-hours trading.

Bank of America has revised its stock price target for the company Hims & Hers.

Hims & Hers Health, Inc. stock saw a rise after J.P. Morgan initiated coverage with an Overweight rating, citing a rich catalyst path for the company.

Shares of Hims & Hers Health experienced a decline on April 21 after Amazon introduced a new competing weight loss program, impacting investor sentiment.

Hims & Hers shares surged 9% as investors showed strong confidence in the company's peptide pipeline and a potential deal with Novo Nordisk.

Shares of Hims & Hers surged after the FDA initiated a review of restricted peptide compounds. The FDA is reportedly set to discuss easing these restrictions at an anticipated July meeting, a move influenced by RFK Jr.'s advocacy for greater accessibility, though experts caution about potential risks.

RFK Jr.'s peptide policy could provide a growth opportunity for Hims & Hers as its GLP-1 business evolves, with an FDA review expected in 2026.

The U.S. Food and Drug Administration is moving forward with plans to reassess restrictions on certain popular peptides, including scheduling an Advisory Committee meeting to decide on potentially lifting them. This development has led to a jump in Hims & Hers stock.

Hims & Hers (HIMS) shares soared by 6% after the company announced its entry into the lucrative $200-billion weight loss market.

Hims & Hers Health has announced it is now selling Novo Nordisk's popular weight-loss medications, Wegovy and Ozempic, expanding access to these treatments.

Hims & Hers (HIMS) is experiencing renewed analyst optimism following a resolution related to Novo Nordisk.

These are the stocks posting the largest moves in early trading.

Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration  AP News

Hims & Hers stock experienced a significant 40% surge following a 'GLP-1 truce'.

An analysis suggests that Hims & Hers Health's expansion into the GLP-1 business may not materialize quickly enough to mitigate associated risks.

A Yahoo Finance article highlights Hims & Hers as a significant telehealth growth story that younger investors should consider, focusing on the company's financial performance and market potential.

These are the stocks posting the largest moves in early trading.

The market saw Hims & Hers stock slide while Domino's rose, as investors anticipate a crucial update from Nvidia amidst a busy earnings season.

Hims & Hers Health, Inc. (HIMS) has announced a 2026 revenue forecast that surpasses market estimates, indicating strong projected financial performance.

Analysts are projecting a significant upside for Hims & Hers stock despite its current performance, with some seeing nearly 150% potential growth.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers announced its plan to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers, a telehealth platform, is set to acquire Australian health tech company Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers is investing more than $1 billion to expand its global footprint, including a significant acquisition of an Australia-based telehealth company.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers' strategy involving GLP-1 pills has reportedly backfired, leading to increased scrutiny and a crackdown on drug compounders.

Despite a 48% selloff this month, Wall Street analysts see an 84% upside potential for Hims & Hers (HIMS) stock.

Telehealth company Hims & Hers is entering the Australian market to drive revenue growth, though analysts caution that successful execution and local competition will determine long-term profitability.

The telehealth company's weight-loss subscription plans are facing scrutiny and penalties following widespread customer disputes processed through Visa.

Visa has placed Hims & Hers Holdings in a restricted payment status, raising concerns about the telehealth provider's transaction capabilities and broader implications for digital health payment networks.

Hims & Hers Health is reportedly facing potential penalties from Visa due to a surge in credit card disputes. This situation could impact the company's financial operations and relationship with the payment processor.

Multiple companies, including Pixelworks, Inuvo, and B&G Foods, have reported their Q2 2026 earnings, with some missing revenue or EPS estimates. Others, like Arq and Janus, provided revenue and adjusted EBITDA targets for 2026.

Rocket Lab has projected its revenue for the third quarter of 2026 to be between $250 million and $265 million, while also targeting a mid-2027 close for its Iridium mission.

Hims & Hers has increased its annual forecast revenue, attributing the positive outlook to robust growth in its subscriber base.

HIMS stock is under scrutiny as the Federal Trade Commission (FTC) has initiated a lawsuit targeting the business practices of Hims & Hers.

The Federal Trade Commission (FTC) has filed a lawsuit against Hims & Hers, a telehealth company, alleging improper health data sharing and problematic billing practices.

An FDA panel has narrowly voted to back four peptides, bringing the stock of companies like Hims & Hers into the spotlight.

Hims & Hers, a telehealth company, announced the departure of its chief accounting officer, who played a key role in the company's initial public offering.

Multiple articles provide analysis on various stocks, including high-growth AI companies, Visa, SoundHound AI, Western Digital, DNOW, HEICO, Spotify, TransAlta, Applied Materials, CoreWeave, Honeywell, and Illinois Tool Works, evaluating their potential as investment opportunities.

Bank of America analysts suggest Hims & Hers faces a significant challenge to meet its 2026 financial guidance, citing potential churn risk related to the weight-loss drug Wegovy.

Hims & Hers has announced the launch of generic versions of Novo's semaglutide in Canada. This move expands access to the medication in the Canadian market.

This week's notable healthcare headlines highlight developments concerning UnitedHealth, Bristol Myers Squibb, and Hims & Hers.

Bank of America has lowered its price target for Hims & Hers, Inc. after the company reported mixed quarterly earnings that reset market expectations.

Hims & Hers Health stock experienced a significant crash. The article aims to explain the reasons behind this notable decrease in share value.

Hims & Hers Health, Inc. has released its summary for the Q1 2026 earnings call.

Hims & Hers has provided a 2026 revenue forecast of $2.8 billion to $3.0 billion, aiming to add over 100,000 weight loss subscribers monthly.

An analysis compares the revenue performance of GoodRx and Hims & Hers Health, highlighting stagnation in one company versus growth in the other.

Several stocks, including Intel, AMD, Charter, Hims & Hers, and Eli Lilly, are experiencing notable movements in midday trading.

The stock price of Hims & Hers Health, Inc. reacted strongly following a crucial review by the U.S. Food and Drug Administration. The market's response indicates the significance of the FDA's findings for the company's future.

An analysis questions whether Amazon's recent actions have negatively impacted the future growth potential of Hims & Hers.

Shares of Hims & Hers (HIMS) experienced a significant 48% jump in value in anticipation of the company's upcoming earnings report.

Hims & Hers Health saw its stock jump following news of the FDA's review of compounded peptide therapies, indicating market reaction to potential regulatory developments in the wellness sector.

Bank of America has increased its price target for Hims & Hers to $25, citing the FDA's recent move towards wellness peptides as a potential catalyst for a new revenue boom for the health company.

Shares of Hims & Hers Health Inc. surged following news that Robert F. Kennedy Jr. is seeking to ease regulations on peptides, a move that could benefit the telehealth company.

A new partnership with Novo is fueling long-term optimism for Hims & Hers Health, Inc. (HIMS), suggesting positive future growth prospects for the company.

Hims & Hers (HIMS) stock experienced an 8.86% tumble, driven by a broader market downturn and significant profit-taking by investors.

A new deal between pharmaceutical giant Novo Nordisk and health platform Hims & Hers is expected to yield positive outcomes for the stock performance of both companies.

Barclays has increased its price target for Hims & Hers (HIMS) to $29 following the clearance of a legal overhang related to the Novo Nordisk deal, which has also led to a surge in Hims & Hers stock.

Several stocks, including Hims & Hers Health, oil stocks, and Live Nation Entertainment, are making significant moves in premarket trading, with Hims & Hers specifically upgraded to Buy from Hold by Needham.

Hims & Hers stock is currently challenging its 50-day moving average, prompting investors to consider if this indicates a potential turnaround for the telehealth company.

Hims & Hers Surges on Novo Obesity Deal That Ends Public Feud  Bloomberg.com

Barclays has lowered its price target on Hims & Hers Health, Inc. (HIMS) to $25 while keeping an Overweight rating.

After a 70% decline over the past year, questions arise about whether Hims & Hers Health stock can bounce back.

Hims & Hers experienced a significant drop in stock value at market open, attributed to regulatory issues that have negatively impacted its financial outlook for 2026.

Investors are reportedly worried about Hims & Hers' profitability due to its aggressive expansion plans, a recent Super Bowl ad, and increased legal and regulatory scrutiny over its weight-loss drug business.

Hims & Hers Health announced its latest financial results, with GAAP EPS of $0.08, surpassing estimates by $0.03, and revenue of $617.82M, which was in-line with expectations.

Hims & Hers forecasts first-quarter sales below estimates, shares fall  Reuters

Hims & Hers announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers announced its plan to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion, expanding its health and wellness offerings.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

This report highlights key premarket movers in the US stock market, including Carvana, Deere, Hims & Hers, and Walmart.

Hims & Hers Health is being assessed for its potential for sustained long-term growth in the market.

The weight-loss drug market is rapidly expanding globally, with a shift from injections to pills and intense competition between pharmaceutical giants like Novo Nordisk and Eli Lilly. Regulatory scrutiny is also impacting new product offerings in this lucrative sector.

Telehealth provider Hims entered Australia, marking its first major expansion into the Asia-Pacific region.

The Pomerantz Law Firm has initiated securities class action investigations and issued deadline reminders for shareholders across a diverse group of publicly traded companies. The alerts span multiple industries, including healthcare, real estate, and banking, urging affected investors to evaluate their potential claims.

Several companies, including Expedia, Nvidia, Strategy, and Hims & Hers, are making headlines with significant stock movements during midday trading.

Hims & Hers Health and Novo Nordisk A/S, key players in the weight-loss pill market, have seen their stock performance impacted despite rapid growth.

This week's notable healthcare headlines highlight developments concerning companies such as Eli Lilly, Hims & Hers Health, and Merck.

Hims & Hers, a telehealth company, is reportedly planning to expand its offerings by selling compounded peptides, signaling a move into new pharmaceutical products.

Hims & Hers Health, Inc. published a summary of its second-quarter 2026 earnings call, covering its financial performance and strategic initiatives.

An analysis explores why Hims & Hers could be an ideal acquisition target, regardless of whether a deal materializes.

US authorities are suing the American online pharmacy Hims & Hers for allegedly sharing sensitive health information of its customers.

The Federal Trade Commission (FTC) claims telehealth company Hims & Hers charged patients without consent and allegedly shared health data with major tech companies.

Hims & Hers Health (HIMS) stock declined after the FDA reportedly gave a 'cold shoulder' to a peptide developed by the company.

An analysis questions if Hims & Hers Health, Inc. (HIMS) is a top weight loss stock following an increase in its target price by Barclays.

Hims & Hers is entering the Australian, Canadian, and Japanese markets through its acquisition of Eucalyptus, marking a significant international expansion.

Hims & Hers CEO is developing new strategies to disrupt traditional healthcare, building on its success in weight-loss markets via telehealth. The company plans to integrate peptides, pending FDA authorization, into its shift towards wellness and longevity.

Several companies, including Onto Innovation, Hims & Hers Health, and Akamai, have announced or priced significant offerings of convertible senior notes. These financial moves aim to raise capital through debt instruments.

Shares of Hims & Hers experienced a decline following the release of its latest earnings report. The market reaction has prompted questions among investors regarding whether this presents a buying opportunity or a warning sign for the company's future.

Shares of Hims & Hers continued to decline, breaking below a key technical level following the company's recent earnings report which missed analyst expectations.

JPMorgan has reduced its price target for Hims & Hers, attributing the adjustment to a shift in the GLP-1 market that is reshaping the company's growth narrative.

Shares of Hims & Hers plummeted significantly after the company reported a quarterly loss and failed to meet sales expectations. The weak financial performance also led to a cautious earnings guidance.

Hims & Hers reported revenue figures that fell short of market estimates, attributed to a recent shift in the company's strategic approach impacting sales performance.

A series of financial articles provides analysis on whether various company stocks, including major players like Apple, Tesla, and Nvidia, represent good investment opportunities. These reports offer insights into potential buys in the current market.

JPMorgan has initiated coverage of Hims & Hers with an Overweight rating, prompting speculation on whether a deal with Novo Nordisk could mark a turning point for the company.

Hims & Hers is significantly increasing its investment and focus on estrogen patches as the demand for these products continues to surge.

Hims & Hers stock experienced a significant surge of 50% in one week, attributed to comments made by RFK Jr. regarding peptides.

Cedar Grove Capital Management reportedly profited from its short position in Hims & Hers Health, indicating a successful bearish bet on the telehealth company.

Robert F. Kennedy Jr.'s actions have caused a significant jolt in Hims & Hers stock, prompting discussions on whether investors should pursue the rally.

Hims & Hers is poised for further stock gains as Robert F. Kennedy Jr. advocates for less stringent regulations on peptides, potentially impacting the company's market.

The price target for Hims & Hers has been reduced, reportedly due to the company's transition related to GLP-1 medications.

Hims & Hers has announced a shift in its business model, a development that comes after a recent deal involving Novo.

Yahoo Finance highlights two S&P 500 stocks for investors to monitor this week, following an unexpected development with Hims & Hers stock.

Hims & Hers experienced its strongest weekly stock gain following the announcement of a deal with Novo Nordisk.

Several stocks, including Bumble, Hims & Hers Health, Blue Owl, and Netskope, are making significant moves in premarket trading, indicating potential volatility for the upcoming trading session.

An asset manager has divested its holdings in Hims & Hers Health, indicating a significant change in investment strategy for the healthcare company's stock.

Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers  WSJ

Hims & Hers is being highlighted as a potential direct-to-consumer health 'moonshot' investment opportunity.

Hims & Hers Health, Inc. has provided a summary of its earnings call for the fourth quarter of 2025.

Hims & Hers (HIMS) has released its earnings call transcript, providing details on the company's financial performance and future outlook.

This article provides a summary of significant corporate deals and transactions that occurred this week, featuring companies such as Visa, Hims & Hers Health, and Salesforce.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion, signaling a major expansion in its market presence.

Hims & Hers announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion, expanding its presence in the health and wellness market.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers announced its plan to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Deutsche Bank expressed near-term growth concerns for Hims & Hers Health, Inc. (HIMS) following the reversal of its GLP-1 launch.

Hims & Hers is making a strategic move to disrupt the pharmaceutical and pharmacy industries by focusing on making longevity treatments more affordable and accessible.